Alnylam Pharmaceuticals Inc.

RNAi therapeutics pioneer with six approved siRNA medicines (Amvuttra/Onpattro for ATTR amyloidosis, Givlaari, Oxlumo, Qfitlia, and partnered Leqvio for hypercholesterolemia) and a deep clinical pipeline spanning cardiometabolic, CNS, and rare disease. Following Amvuttra's HELIOS-B win in ATTR-CM, the company unveiled its "Alnylam 2030" strategy targeting 25%+ revenue CAGR and TTR market leadership.